GlobalData on MSN
FDA clears Cepheid’s Xpert GI Panel for pathogen detection
The Xpert GI Panel identifies pathogens directly from stool specimens collected in Cary-Blair transport media.
The Danaher subsidiary aims to meet clinician needs for flexibility with a range of test size options for its vast installed base.
Panel delivers rapid detection of five common bacterial pathogens for outpatient use, aiding fast and informed treatment decisions QIAGEN building momentum in the U.S. syndromic testing market with ...
BEVERLY, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc. (LXXGF), (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative ...
SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode, a leader in molecular diagnostics panel testing, is excited to announce a significant enhancement to its BioCode ® Gastrointestinal Pathogen ...
Background. Molecular syndromic diagnostic panels can enhance pathogen identification in the approximately 2–4 billion episodes of acute gastroenteritis that occur annually worldwide. However, the ...
Hologic has won clearance for the Panther Fusion Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays. The Marlborough, MA-based company said it has also obtained CE marking in accordance ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results